SNBL Reports Results For Phase 2 Clinical Study Of Intranasal Granisetron
Shin Nippon Biomedical Laboratories (SNBL) is developing an intranasal form of the antiemetic drug, granisetron (TRG) in the US. SNBL has announced the first report on the results
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.